Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171899
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-09-13
Brief Title:
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive Ph Chronic Myelogenous Leukemia CML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CSTI571ACA09
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None